ClinicalTrials.gg
RecruitingNCT05509153NAC-preHDUpdated Feb 28, 2025

A Randomised Controlled Trial, of N-Acetyl Cysteine (NAC), for Premanifest Huntingtin Gene Expansion Carriers

A Phase 2 interventional study of NAC and Placebo in Huntington Disease, sponsored by Western Sydney Local Health District. Recruiting at 5 sites in Australia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-02-28.

Sponsored by Western Sydney Local Health District · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Huntington Disease with a site in Australia — 5 open to participants now, 9 under way, 3 of them phase 3. Huntington Disease · Australia.

Planned enrollment
10th of 24
160 · median 149
Started
2024
with 1 other
Phase 2
8 of 28
1 open now
Registered
19th of 28
by date

Among the 28 studies in Huntington Disease with a site in Australia, this one is the 10th largest by planned enrollment of the 24 interventional ones that give a count, is one of 2 that started in 2024, is one of 8 in phase 2, and was the 19th registered.

Huntington Disease

293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.

Browse Huntington Disease studies →

Open to participants now

5 of the 28 studies in Huntington Disease with a site in Australia are open now. Recruiting first, the newest first:

All 5 open studies →

A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →

Who these studies take

Of the 43 Huntington Disease studies recruiting now, 19 (44%) set no upper age limit and 20 (47%) stop at 75 or younger; 5 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Huntington Disease with a site in Australia, or all of them as a file.
02

Study summary

NAC-preHD is a phase II randomized placebo controlled study of oral NAC among premanifest HD gene expansion carriers, with clinical and radiological outcome at three years.

03

Conditions studied

  • Huntington Disease

Browse trials for

Keywords

  • N-Acetylcysteine
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to provide
  • Huntingtin gene expansion carrier with >= 39 CAG repeats
  • Absence of unequivocal motor signs of HD - that is, UHDRS
  • Diagnostic Confidence Level needs to be \<4 upon enrolment
  • Expected to develop clinical HD within 10 years of trial enrolment using the Langbehn formula
  • Availability of an informant for corroborative history
  • Negative serum pregnancy test for women of
  • If of childbearing potential, is able and agrees to remain abstinent or use adequate methods
  • Ability to tolerate MRI scans
  • Ability to tolerate blood draws
  • Able to comply with all study protocol requirements, according to the investigators judgement
  • In the opinion of the investigator, medically, psychiatrically and neurologically stable at the time of enrolment

Exclusion criteria

Exclusion Criteria:

  • Diagnosis of clinical HD
  • Known to NAC
  • Pregnancy, breastfeeding or intention to do so prior to the end of the study
  • Exposure to any drugs within 30 days of Baseline Visit
  • Use of supplemental NAC
  • Abnormalities in laboratory measurements, or vital signs at screening, which precludes safe participation in the study
  • Current or history of substance abuse within one year of Baseline visit
  • Unstable psychiatric or acute medical illness including cancer, as determined by investigator
  • Current use of antipsychotic medications or Tetrabenazine
  • History of gene therapy, cell transplantation, or any experimental brain surgery
  • History of attempted suicide or suicidal ideation within 12 months prior to screening
  • Pre-existing structural brain lesion as assessed by a centrally read MRI scan during the screening period
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    NAC

    1g N-Acetylcysteine capsules, taken orally twice a day.

    Drug: NAC

  • Placebo comparator
    Placebo

    Coated Placebo capsules, taken orally twice a day

    Drug: Placebo

Interventions

  • DrugAcetylcysteineStudies of AcetylcysteineAcetylcysteine pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    1g of clinical grade N-Acetylcysteine capsules, taken orally twice a day

    Also known as: N-Acetylcysteine

  • DrugPlacebo

    Coated Placebo capsules, manufactured to match appearance and taste, taken orally twice a day

06

What researchers measure

Primary outcomes

  1. Caudate Atrophy Rate on volumetric MRI

    Blinded assessment

    Time frame: Baseline through end of study (up to 3 years)

  2. Rate of motor phenoconversion

    Defined by conversion to Diagnostic Confidence Level 4, upon blinded assessment using the UHDRS motor subscale

    Time frame: Baseline through end of study (up to 3 years)

Secondary outcomes

  1. UHDRS motor subscale (total score)

    Measuring changes in motor function

    Time frame: Baseline through end of study (up to 3 years)

  2. Stroop Word

    Change in cognition as measured by Stroop Word

    Time frame: Baseline through end of study (up to 3 years)

  3. Trail Making Test

    Change in cognition as measured by Trail Making Test

    Time frame: Baseline through end study (up to 3 years)

  4. Montreal Cognitive Assessment

    Change in cognition as measured by Montreal Cognitive Assessment

    Time frame: Baseline through end of study (up to 3 years)

  5. Symbol Digit Modality Test

    Change in cognition as measured by Symbol Digit Modality Test

    Time frame: Baseline through end of study (up to 3 years)

  6. Changes in Mood and Behavioural symptoms

    Evaluated using the PBA-s, a semi-structured interview behavioural scale

    Time frame: Baseline through end of study (up to 3 years)

  7. Changes in Daily Function

    Measured using the Total Functional Capacity and Independent Scale from the broader UHDRS and the Functional Rating Scale for HD

    Time frame: Baseline through end of study (up to 3 years)

  8. Change to Quality of Life

    As measured by the standardised questionnaires, HDQoL and EQ-5D

    Time frame: Baseline through end of study (up to 3 years)

  9. Study completion (Safety and Tolerability)

    Measured by the proportion of participants completing NAC arm of study

    Time frame: Baseline through end of study (up to 3 years)

  10. Incidence of abnormal laboratory values and/or 12-lead ECG changes (Safety and Tolerability)

    Measured by the Number of participants with abnormal laboratory values and/or 12-lead ECG changes compared to baseline

    Time frame: Baseline through end of study (up to 3 years)

  11. Incidence of adverse and/or serious adverse events (Safety and Tolerability)

    Measured by the number of adverse and/or serious adverse events

    Time frame: Baseline through end of study (up to 3 years)

07

Study locations

1 of 5 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — Currently not included in ethics approval but to be investigated.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2024 (actual). Primary completion is estimated for Nov 2026, 29 months after the start.

Of 22 phase 2 interventional studies under Huntington Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's planned 29 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2022
First posted
Aug 19, 2022
StartActual
Jun 1, 2024
Primary completionEst.
Nov 1, 2026
CompletionEst.
May 1, 2027
Last update
Feb 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05509153
Lead sponsor
Western Sydney Local Health District
Collaborators
Deakin University, Monash University, Royal Perth Hospital, The University of Queensland, University of Melbourne
Responsible party
Clement Loy (Director and Neurologist, Huntington Disease Service, Western Sydney Local Health District) — Principal investigator
First posted
Aug 19, 2022
Start date
Jun 1, 2024
Primary completion
Nov 1, 2026 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Feb 28, 2025

Study contacts

Clement Loy
Contact
clement.loy@sydney.edu.au
001164 4 8890 3560
Sarah Samperi
Contact
sarah.samperi@health.nsw.gov.au
001164 2 8890 9146
Clement Loy
principal investigator · University of Sydney
Yenni Lie
principal investigator · Calvary Health Care Bethlehem
Dennis Velakoulis
principal investigator · Melbourne Health
Carolyn Orr
principal investigator · Perron Institute
John O'Sullivan
principal investigator · The University of Queensland
Rob Adam
principal investigator · The University of Queensland

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetylcysteine

Start the discussion